Pathogenesis of inclusion bodies in (CAG)(n)/Q(n)-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability

Journal of Neurochemistry

Volumn 72, Issue 3, 1999, Pages 889-899

  Cooper, Arthur J L ^a,e   Sheu, Kwan Fu Rex ^a   Burke, James R ^b   Strittmatter, Warren J ^b   Gentile, Vittorio ^c   Peluso, Gianfranco ^d   Blass, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d CNR   (Italy)

^e BURKE MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

(CAG)(n) expansion diseases; Huntington disease; Neurodegenerative diseases; Nuclear inclusions; Polyglutamine domains; Tissue transglutaminase

Indexed keywords

GLUTAMINASE; GLUTAMINE DERIVATIVE; REPETITIVE DNA;

APOPTOSIS; CELL INCLUSION; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; DEGENERATIVE DISEASE; ENZYME LOCALIZATION; ENZYME SUBSTRATE; HUMAN; HUNTINGTON CHOREA; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY;

ANIMALS; HUMANS; INCLUSION BODIES; NEURODEGENERATIVE DISEASES; TRANSGLUTAMINASES; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 0033012131     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.0720889.x     Document Type: Short Survey

References (98)

1. Abdullah A., Trifiro M. A., Panet-Raymond V., Alvarado C., de Tourreil S., Frankel D., Schipper H. M., and Pinsky L. (1998) Spinobulbar muscular atrophy: polyglutamine-expanded androgen receptor is proteolytically resistant in vitro and processed abnormally in transfected cells. Hum. Mol. Genet. 7, 379-384.
2. Aeschlimann D. and Paulsson M. (1994) Transglutaminases: protein cross-linking enzymes in body fluids. Thromb. Haemost. 71, 402-414.
3. Akiyama H., Kondo H., Ikeda K., Arai T., Kato M., and McGreer P. L. (1995) Immunohistochemical detection of factor XIIIa in post-mortem brain tissue. Neurosci. Lett. 202, 29-32.
4. Appelt D. M. and Balin B. J. (1997) The association of tissue transglutaminase with human recombinant tau results in the formation of insoluble filamentous structures. Brain Res. 745, 21-31.
5. Ballestar E. and Franco L. (1997) Use of the transglutaminase reaction to study the dissociation of histone N-terminal tails from DNA in nucleosome core particles. Biochemistry 36, 5963-5969.
6. Ballestar E., Abad C., and Franco L. (1996) Core histones are glutaminyl substrates for tissue transglutaminase. J. Biol. Chem. 271, 18817-18824.
7. Baradet T. C., Loewy A. G., Mawal-Dewan M., Appelt D. M., and Balin B. J. (1997) Polymers of beta amyloid 1-40 protein cross-linked by plasma transglutaminase are dissociated by isopeptidase enzymes. Soc. Neurosci. Abstr. 23, 1631.
8. Bates G. P., Mangiarini L., Mahal A., and Davies S. W. (1997) Transgenic models in Huntington's disease. Hum. Mol. Genet. 6, 1633-1637.
9. Beal M. F. (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38, 357-366.
10. Becher M. W., Kotzuk J. A., Sharp A. H., Davies S. W., Bates G. P., Price D. L., and Ross C. A. (1998) Intranuclear neuronal nuclear inclusions in Huntington's disease and DRPLA: correlation between the density of the inclusions and IT15CAG triplet length. Neurobiol. Dis. 4, 387-397.
11. Brandt J., Bylsma F. W., Gross R., Stine O. C., Ranen N., and Ross C. A. (1996) Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 46, 527-531.
12. Browne S. E., Bowling A. C., MacGarvey U., Baik M. J., Berger S. C., Muqit M. M. K., Bird E. D., and Beal M. F. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646-653.
13. Burke J. R., Enghild J. J., Martin M. E., Jou Y.-S., Myers R. M., Roses A. D., Vance J. M., and Strittmatter W. J. (1996) Huntingtin and DRPLA proteins selectively interact with the protein GAPDH. Nat. Med. 2, 347-350.
14. Chung S. I. (1972) Comparative studies on tissue transglutaminase and factor XIII. Ann. NY Acad. Sci. 202, 240-255.
15. Cooper A. J. L., Sheu K.-F. R., Burke J. R., Onodera O., Strittmatter W. J., Roses A. D., and Blass J. P. (1997a) Polyglutamine domains are substrates of tissue transglutaminase. Does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases? J. Neurochem. 69, 431-434.
16. Cooper A. J. L., Sheu K.-F. R., Burke J. R., Onodera O., Strittmatter W. J., Roses A. D., and Blass J. P. (1997b) Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and α-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. Proc. Natl. Acad. Sci. USA 94, 12604-12609.
17. Cooper A. J. L., Sheu K.-F. R., Burke J. R., Onodera O., Strittmatter W. J., Roses A. D., and Blass J. P. (1998) Inhibition of α-ketoglutarate- and pyruvate dehydrogenase complexes in E. coli by a glutathione S-transferase containing a pathological-length poly-Q domain: a possible role of energy deficit in neurolgical diseases associated with poly-Q expansions? Age 21, 25-30.
18. Cummings C. J., Mancini M. A., Antalffy B., DeFranco D. B., Orr H. T., and Zoghbi H. Y. (1998) Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 19, 148-154.
19. Davies S. W., Turmaine M., Cozens B. A., DiFiglia M., Sharp A. H., Ross A., Scherzinger E., Wanker E. E., Mangiarini L., and Bates G. P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548.
20. Davies S. W., Beardsall K., Turmaine M., DiFiglia M., Aronin N., and Bates G. P. (1998) Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet 351, 131-133.
21. DiFiglia M., Sapp E., Chase K. O., Davies S. W., Bates G. P., Vonsattel J. P., and Aronin N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neuntes in brain. Science 277, 1990-1993.
22. Dragunow M., Faull R. L., Lawlor P., Beilharz E. Z., Singleton K., Walker E. B., and Mee E. (1995) In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer disease temporal lobes. Neuroreport 6, 1053-1057.
23. Dudek S. M. and Johnson G. V. W. (1993) Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of τ. J. Neurochem. 61, 1159-1162.
24. Dudek S. M. and Johnson G. V. W. (1994) Transglutaminase facilitates the formation of polymers of the β-amyloid peptide. Brain Res. 651, 129-133.
25. 5)spermine derivatives of substance P. J. Neurochem. 65, 420-426.
26. Facchiano F., Benfenati F., Valtorta F., and Luini A. (1993) Covalent modification of synapsin 1 by tetanus toxin-activated transglutaminase. J. Biol. Chem. 268, 4588-4595.
27. Ferrante R. J., Gutenkunst C. A., Persichetti F., McNeil S. M., Kowall N. W., Gusella J. F., MacDonald M. E., Beal M. F., and Hersch S. M. (1997) Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostratum. J. Neurosci. 17, 3052-3062.
28. Fésus L., Davies P. J. A., and Piacentini M. (1991) Apoptosis: molecular mechanisms in programmed cell death. Eur. J. Cell Biol. 56, 170-177.
29. Fink M. L. and Folk J. E. (1981) γ-Glutamylamine cyclotransferase - an enzyme involved in the catabolism of ε-(-γ-glutamyl) lysine and other γ-glutylamines. Mol. Cell. Biochem. 38, 59-67.
30. Folk J. E. (1969) Mechanism of action of guinea pig liver transglutaminase. J. Biol. Chem. 244, 3707-3713.
31. Folk J. E. and Cole P. W. (1966) Transglutaminase: mechanistic features of the active site as determined by kinetic and inhibitor studies. Biochim. Biophys. Acta 122, 244-264.
32. Folk J. E. and Finlayson J. S. (1977) The ε-(γ-glutamyl)lysine cross-link and the catalytic role of transglutaminases. Adv. Protein Chem. 31, 1-133.
33. Gentile V., Thomazy V., Piacentini M., Fésus L., and Davies P. J. A. (1992) Expression of tissue transglutaminase in Balb-c 3T3 fibroblasts: effects on cellular morphology and adhesion. J. Cell Biol. 119, 463-474.
34. Gentile V., Sepe C., Calvani M., Melone M. A. B., Cotrufo R., Cooper A. J. L., Blass J. P., and Peluso G. (1998) Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. Arch. Biochem. Biophys. 352, 314-321.
35. Goldberg Y. P., Nicholson D. W., Rasper D. M., Kalchman M. A., Koide H. B., Graham R. K., Bromm M., Kazemi-Esfajani P., Thornberry N. A., Vaillancourt J. P., and Hayden M. R. (1996) Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat. Genet. 13, 442-449.
36. Gomez C. M., Thompson R. M., Gammack J. T., Perlman S. L., Dobyns W. B., Truwit C. L., Zee D. S., Clark H. B., and Anderson J. H. (1997) Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset. Ann. Neurol. 42, 933-950.
37. Green H. (1993) Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell 74, 955-956.
38. Grootjans J. J., Groenen P. J. T. A., and de Jong W. W. (1995) Substrate requirements for transglutaminases. Influence of the amino acid residue preceding the amine donor lysine in a native protein. J. Biol. Chem. 270, 22855-22858.
39. Igarashi S., Koide R., Shimohata T., Yamada M., Hayashi Y., Takano H., Date H., Oyake M., Sato T., Sato A., Egawa S., Ikeuchi T., Tanaka H., Nakano R., Tanaka K., Hozumi I., Inuzuka T., Takahashi H., and Tsuji S. (1998) Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat. Genet. 18, 111-117.
40. h hydrolyzes GTP and ATP. Biochemistry 36, 11655-11664.
41. Ikeda H., Yamaguchi M., Sugai S., Aze Y., Narumiya S., and Kakizuka A. (1996) Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat. Genet. 13, 196-202.
42. 1A voltage-dependent calcium channel gene and clinical variations in Japanese populations. Ann. Neurol. 42, 879-884.
43. Ikura K., Kita K., Fujita I., Hashimoto H., and Kawabata N. (1998) Identification of amine acceptor protein substrates of transglutaminase in liver extracts: use of 5-(biotinamido)pentylamine as a probe. Arch. Biochem. Biophys. 356, 280-286.
44. Jackson M., Gentleman S., Lennox G., Ward L., Gray T., Randall K., Morrell K., and Lowe J. (1995) The cortical neuritic pathology of Huntington's disease. Neuropathol. Appl. Neurobiol. 21, 18-26.
45. Johnson G. V. W., Cox T. M., Lockhart J. P., Zinnerman M. D., Miller M. L., and Powers R. E. (1997) Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res. 751, 323-329.
46. Kahlem P., Terré C., Green H., and Djian P. (1996) Peptides containing glutamine repeats are substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc. Natl. Acad. Sci. USA 93, 14580-14585.
47. Kahlem P., Green H., and Djian P. (1998) Transglutaminase action imitates Huntington's disease: selective polymerization of huntingtin containing polyglutamine. Mol. Cell 1, 595-601.
48. Karpuj M. V., Garren H., Slunt H., Price D., Gusella J., and Steinman L. (1999) Transglutaminase aggregates huntingtin into non-amyloidogenic polymers and its enzymatic activity is increased in Huntington's disease brain. Proc. Natl. Acad. Sci. (submitted).
49. Koshy B., Matilla T., Burright E. N., Merry D. E., Fischbeck K. H., Orr H. T., and Zoghbi H. Y. (1996) Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde 3-phosphate dehydrogenase. Hum. Mol. Genet. 5, 1311-1318.
50. Kosinski C. M., Cha J. H., Young A. B., Persichetti F., MacDonald M., Gusella J. F., Penney J. B. Jr., and Standaert D. G. (1997) Huntingtin immunoreactivily in the rat neostriatum: differential accumulation in projection and interneurons. Exp. Neurol. 144, 239-247.
51. Lesort M., Attanavanich K., Zhang J., and Johnson G. V. W. (1998) Distinct nuclear localization and activity of tissue transglutaminase. J. Biol. Chem. 273, 11991-11994.
52. Li X.-J., Sharp A. H., Li S.-H., Dawson T. M., Snyder S. H., and Ross C. A. (1996) Huntingtin-associated protein (HAP1): discrete neuronal localizations in the brain resemble those of neuronal nitric oxide synthase. Proc. Natl. Acad. Sci. USA 93, 4839-4844.
53. Lorand L. (1996) Neurodegenerative diseases and transglutaminase. Proc. Natl. Acad. Sci. USA 93, 14310-14313.
54. Lunkes A. and Mandel J.-L. (1997) Polyglutamines, nuclear inclusions and neurodegeneration. Nat. Med. 3, 1201-1202.
55. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S. W., and Bates G. P. (1996) Exon I of the HD gene with an expanded CAG repeat is sufficient to cause progressive neurological phenotype in transgenic mice. Cell 87, 493-506.
56. Martindale D., Hackam A., Wieczorek A., Ellerby L., Wellington C., McCutcheon K., Singaraja R., Kazemi-Esfarjani P., Devon R., Kim S. U., Bredesen D. E., Tufaro F., and Hayden M. R. (1998) Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet. 18, 150-154.
57. Matilla A., Koshy B. T., Cummings C. J., Isobe T., Orr H. T., and Zoghbi H. Y. (1997) The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 389, 974-978.
58. Mhatre A. N., Trifiro M. A., Kaufman M., Kazemi-Esfarani P., Figlewicz D., Rouleau G., and Pinsky L. (1993) Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat. Genet. 5, 184-188.
59. Miller C. C. J. and Anderton B. H. (1986) Transglutaminase and the neuronal cytoskeleton in Alzheimer's disease. J. Neurochem. 46, 1912-1922.
60. Miller M. L. and Johnson G. V. W. (1995) Transglutaminase cross-linking of the τ protein. J. Neurochem. 65, 1760-1770.
61. Miller M. L., Zhang J., and Johnson G. V. W. (1997) Modification of tau in situ by activation of transglutaminase. Soc. Neurosci. Abstr. 23, 1643.
62. Ohashi H., Itoh Y., Birckbichler P. J., and Takeuchi Y. (1995) Purification and characterization of rat brain transglutaminase. J. Biochem. (Tokyo) 118, 1271-1278.
63. Onodera O., Roses A., Tsuji S., Vance J. M., Strittmatter W. J., and Burke J. R. (1996) Toxicity of expanded polyglutamine-domain proteins in Escherichia coli. FEBS Lett. 399, 135-139.
64. Onodera O., Burke J. R., Miller S. E., Hester S., Tsuji S., Roses A. D., and Strittmatter W. J. (1997) Oligomerization of expanded-polyglutamine domain fluorescent fusion proteins in cultured mammalian cells. Biochem. Biophys. Res. Commun. 238, 599-605.
65. Ordway J. M., Tallaksen-Greene S., Gutekunst C.-A., Bernstein E. M., Cearley J. A., Wiener H. W., Dure L. S. IV, Lindsey R., Hersch S. M., Jope R. S., Albin R., and Detloff P. J. (1997) Ectopically expressed CAG repeats cause intranuclear inclusions and progressive late onset neurological phenotype in the mouse. Cell 91, 753-763.
66. Pastuzsko A., Wilson D. F., and Erecińska M. A. (1986) Role of transglutaminase in neurotransmitter release by rat brain synaptosomes. J. Neurochem. 46, 499-508.
67. Paulson H. L. and Fishbeck K. H. (1996) Trinucleotide repeats in neurogenetic disorders. Annu. Rev. Neurosci. 19, 79-107.
68. Paulson H. L., Perez M. K., Trottier Y., Trojanowski J. Q., Subramony S. H., Das S. S., Vig P., Mandel J. L., Fischbeck K. H., and Pittman R. N. (1997a) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19, 333-344.
69. Paulson H. L., Das S. S., Crino P. B., Perez M. K., Patel S. C., Gotsdiner D., Fischbeck K. H., and Pittman R. N. (1997b) Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann. Neurol. 41, 453-462.
70. Perutz M. F. (1996) Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Curr. Opin. Struct. Biol. 6, 848-858.
71. Perutz M. F., Johnson T., Suzuki M., and Finch J. T. (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 91, 5355-5358.
72. Porta R., Gentile V., Esposito C., Fusco A., Peluso G., and Metafora S. (1988) B-Lipoprotein 61-76 and 61-91 fragments act as transglutaminase substrates in vitro. Neuropeptides 11, 89-92.
73. Portera-Cailliau C., Hedreen J. C., Price D. L., and Koliatsos V. E. (1995) Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 15, 3775-3787.
74. Reichelt K. L. and Poulsen E. (1992) γ-Glutamylaminotransferase and transglutaminase in subcellular fractions of rat cortex and in cultured astrocytes. J. Neurochem. 59, 500-504.
75. Ross C. A. (1997) Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 19, 1147-1150.
76. Ross C. A., Becher M. W., Colomer V., Engelender S., Wood J. D., and Sharp A. H. (1997) Huntington's disease and dentatorubral-pallidoluysian atrophy: proteins, pathogenesis and pathology. Brain Pathol. 7, 1003-1006.
77. Sapp E., Ge P., Aizawa H., Bird E., Penney J., Yong A. B., Vonsattel J. P., and DiFiglia M. (1995) Evidence for a preferential loss of enkephalin immunoreactivity in low grade Huntington's disease using high resolution image analysis. Neuroscience 64, 397-404.
78. Sapp E., Schwarz C., Chase K., Bhide P. G., Young A. B., Penney J., Vonsattel J. P., Aronin N., and DiFiglia M. (1997) Huntingtin localization in brains of normal and Huntington's disease patients. Ann. Neurol. 42, 604-612.
79. 180 repeat expansion and the propagation of highly expanded CAG repeats in lambda phage. Hum. Genet. 99, 692-695.
80. Saunders P. A., Chalecka-Franaszek E., and Chuang D.-M. (1997) Subcellular distribution of glyceraldehyde 3-phosphate dehydrogenase in cerebellar granule cells undergoing cytosine arabinoside-induced apoptosis. J. Neurochem. 69, 1820-1828.
81. Sawa A., Khan A. A., Hester L. D., and Snyder S. H. (1997) Glycer-aldehyde-3-phosphate dehydrogenase: nuclear translocation in neuronal and nonneuronal cell death. Proc. Natl. Acad. Sci. USA 90, 549-558.
82. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G. P., Davies S. W., Lehrach H., and Wanker E. E. (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-558.
83. Schöls L., Amoiridis G., Büttner T., Przuntek H., Epplen J. T., and Riess O. (1997) Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes. Ann. Neurol. 42, 924-932.
84. Seiler N. and Deckard K. (1976) Association of putrescine, spermidine and GABA with structural elements in brain cells. Neurochem. Res. 1, 469-499.
85. Selkoe D. J., Ihara Y., and Salazar Y. (1982) Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea. Science 215, 1243-1245.
86. Singh U. S., Erickson J. W., and Cerione R. A. (1995) Identification and characterization of an 80 kilodalton GTP-binding protein/ transglutaminase from adult rabbit liver nuclei. Biochemistry 34, 15863-15871.
87. Skinner P., Koshy B. T., Cummings C. J., Klement I. A. Helin K., Servadio A., Zoghbi H. Y., and Orr H. T. (1997) Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 389, 971-974.
88. Stine O. C., Pleasant M., Franz M. L., Abbott M. H., Folstein S. E., and Ross C. A. (1993) Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum. Mol. Genet. 2, 1547-1549.
89. Stott K., Blackburn J. M., Butler P. J. G., and Perutz M. (1995) Incorporation of glutamine repeats makes protein oligomerize. Implications for neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 92, 6509-6513.
90. Strong T. V., Tagle D. A., Valdes J. M., Elmer L. W., Boehm K., Swaroop M., Kaatz K. W., Collins F. S., and Albin R. L. (1993) Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat. Genet. 5, 259-265.
91. Takehana S., Washizu K., Ando K., Koikeda S., Takeuchi K., Matsui H., Motoko M., and Takagi H. (1994) Chemical synthesis of the gene for microbial transglutaminase from Streptoverticillium and its expression in Escherichia coli. Biosci. Biotech. Biochem. 58, 88-92.
92. Trottier Y., Devys D., Imbert G., Saudou F., An I., Lutz Y., Weber C., Agid Y., Hirsch E. C., and Mandel J.-L. (1995) Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat. Genet. 10, 104-110.
93. Tukamoto T., Nukina N., Ide K., and Kanazawa I. (1997) Huntington's disease gene product, huntingtin, associates with microtubules in vitro. Mol. Brain Res. 51, 8-14.
94. Wellington C. L., Brinkman R. R., O'Kusky J. R., and Hayden M. R. (1997) Toward understanding the molecular pathology of Huntington's disease. Brain Pathol. 7, 979-1002.
95. Wellington C. L. Ellerby L. M., Hackman A. S., Margolis R. L., Trifiro M. A., Singaraja R., McCutcheon A. S., Salvesen G. S., Propp S. S., Bromm M., Rowland K. J., Zhang T., Rasper D., Roy S., Thornberry N., Pinsky N., Kakizuka A., Ross C. A., Nicholson D. W., Bredesen D. E., and Hayden M. R. (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273, 9158-9167.
96. Zhang J., Lesort M., Guttmann R. P., and Johnson G. V. W. (1998) Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J. Biol. Chem. 273, 2288-2295.
97. Zhang W., Johnson B. R., and Bjornsson T. D. (1997) Pharmacologic inhibition of transglutaminase-induced cross-linking of Alzheimer's amyloid β-peptide. Life Sci. 60, 2323-2332.
98. 1A-voltage-dependent calcium channel. Nat. Genet. 15, 62-69.